The Role of Highly Active Antiretroviral Therapy (HAART) on Interleukin 17A (IL-17A) in Normotensive and Preeclamptic Black South African Women

Phoswa, Wendy N.; Naicker, Thajasvarie; Ramsuran, Veron; Moodley, Jagidesa

doi:10.1155/2020/3417632

Cited by 4 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cytokine has potent proinflammatory properties, which have been associated with the development of inflammatory processes, acute immunological graft rejection, and autoimmune diseases such as pre-eclampsia in pregnant females and HIV/AIDS patients. [ 11 ]…”

Section: Discussionmentioning

confidence: 99%

Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study

Maloth

Shrinivas

Pramod

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

Aim: To determine the preponderance of oral mucosal lesions and conditions in patients receiving highly active antiretroviral therapy (HAART) for Human Immunodeficiency virus (HIV). Material and Methods: Patient tested Seropositive for HIV and on HAART therapy were clinically examined to evaluate prevalence of oral lesions. Results: In the pool of 152 HIV positive patients in the study, age ranged from 7 to 71 years, 67 were males and 85 females. The duration of the HAART medication was 43 months. Oral lesion was present in 51.32% of patients related to infection. Oral lesions seen in descending order of frequency were periodontitis, mucosal hyperpigmentation, acute gingivitis, oral candidiasis, linear gingival erythema, stomatitis, and nonspecific ulcers. Totally, 48.68% of patients had no oral lesions. Conclusion: Majority of the HIV patients on HAART exhibited periodontitis (30.77%), mucosal hyperpigmentation (17.44%), gingivitis (10.77%), anemic stomatitis (11.28%), and other oral lesions accounted to 29.74% which may be attributed to Anti Retro Viral Therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study

Maloth

Shrinivas

Pramod

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

show abstract

“…Others enter pregnancy on newer INSTIs, such as bictegravir, which needs further study to determine if it has the same class effects. Although we investigated the role of maternal CD4 + cell count and viral load with HDP risk as crude proxies for the maternal inflammatory state and immune status, future work should address other markers of immune status [33–36] that may better predict HDP and thus allow for the development of targeted interventions. Further work is also required to better understand risk factors for superimposed preeclampsia among individuals who enter pregnancy with chronic hypertension.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the association of antiretroviral therapy and immune status with hypertensive disorders of pregnancy among people with HIV

Yee

Jacobson

Haddad

et al. 2023

Aids

View full text Add to dashboard Cite

The aim of this study was to examine the association of timing of antiretroviral therapy (ART) initiation and ART class with risk of new-onset hypertensive disorders of pregnancy (HDP) among people with HIV (PWH).Design: An observational study of participants in the multisite Surveillance Monitoring for ART Toxicities (SMARTT) study.Methods: Data were abstracted from medical records of pregnant PWH enrolled in SMARTT (January 30, 2015 to March 25, 2019. New-onset HDP included gestational hypertension, preeclampsia/eclampsia, or HELLP syndrome. We examined the associations of clinical risk factors and three exposures of interest, each in a separate model, with risk of new-onset HDP. Log-binomial regression models were fit using generalized estimating equations to account for correlations within people. Exposures included timing of ART initiation, antiretroviral class among those on therapy at conception, and antiretroviral class among those initiating treatment during pregnancy.Results: Of 1038 pregnancies in this cohort, 973 were singletons with complete data on HDP, with ART use in 948. Overall, 9% had a new-onset HDP, 10% had chronic hypertension, and 81% had no hypertension. Diabetes [adjusted relative risk (aRR) 2.44, 95% confidence interval (95% CI) 1.42-4.21] and first/second trimester CD4 þ cell count less than 200 cells/ml (aRR 1.99, 95% CI 1.21-3.27) were associated with a greater risk of new-onset HDP. Risk of new-onset HDP was similar by antiretroviral class, but those initiating ART after 20 weeks' gestation had a greater risk (aRR 1.93, 95% CI 1.12-3.30) compared with those receiving ART at conception. Conclusion:In this large, diverse cohort of pregnant PWH, worse early pregnancy immune status and later ART initiation were associated with an increased risk of HDP while ART class was not.

show abstract

“…For this reason, we aim to characterize the systemic inflammatory profile of pregnant PLWH at two time points during pregnancy using a set of 12 inflammatory mediators known to be associated with HIV-related inflammation and/or adverse pregnancy outcomes. These include pro-inflammatory mediators such as T-helper type 1 cytokine: (IFNγ); inflammation-associated cytokines: IL-1β, IL-6, IL-17, TNFα, and Granulocyte macrophage colony stimulating factor (GM-CSF) which is also an important cell differentiation modulator during pregnancy; Danger associated molecular pattern (DAMP): High mobility group box 1(HMGB1); the immunomodulatory protein alpha-1-acid-glycoprotein (AGP), which is also an acute phase protein produced in response to systemic inflammation; the major marker for acute and chronic inflammation: C-reactive protein (CRP); anti-inflammatory cytokine IL-10, and HIV-suppressive cytokines IFNα and IFNβ ( Kedzierska and Crowe, 2001 ; Robertson, 2007 ; Najat Nakishbandy and Barawi, 2014 ; Osuji et al, 2018 ; Vecchié et al, 2018 ; Equils et al, 2020 ; Pereira et al, 2020 ; Phoswa et al, 2020 ; Saito Reis et al, 2021 ; Vyas et al, 2021 ). We aimed to analyze the levels of these mediators during both the second and third trimesters according to HIV status, class of ART and pregnancy outcome, namely preterm delivery or not.…”

Section: Introductionmentioning

confidence: 99%

Circulating levels of inflammatory mediators in pregnant people living with HIV according to antiretroviral therapy regimen

Hindle,

Girard,

Cote

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionThe use of antiretroviral therapy (ART) during pregnancy, particularly protease-inhibitor-based regimens (PI), has been linked to adverse outcomes including preterm delivery. As this outcome may be related to systemic inflammation, we sought to characterize inflammatory profiles of pregnant people living with HIV (PLWH) by comparing their levels of inflammatory mediators at two timepoints during pregnancy according to ART regimen, and to HIV-negative controls.MethodsSecond and third trimester samples from 144 pregnant PLWH treated with ART and 24 HIV-uninfected controls were retrieved from the CARMA-PREG cohort. Peripheral plasma levels of 12 inflammatory mediators previously linked to HIV infection and/or poor pregnancy outcomes were quantified by multiplex assay: HMGB1, GM-CSF, IFNα, IFNβ, IFNγ, IL-10, IL-17, IL-1β, IL-6, TNFα, AGP, and CRP. Levels were compared by ART regimen and HIV status.ResultsAdjusted analyses showed that PLWH have higher levels of AGP throughout pregnancy and lower levels of IFNγ and IL-1β during the second trimester. PI-based regimens are associated with significantly higher levels of IFNα and IL-17 during the second trimester and IFNα, CRP, HMGB1, and IFNβ during the third trimester compared to InSTI-based regimens. The PI-subgroup was associated with preterm delivery and higher HIV-1 viral load.DiscussionOur results suggest that PI-based regimens are associated with a pro-inflammatory and antiviral immunological response and a high viral load, which may be a mechanism through which PI-based regimens increase the risk of preterm delivery. Further investigations into cellular mechanisms and pro-inflammatory cascades leading to preterm delivery are necessary to support this association.

show abstract

The Role of Highly Active Antiretroviral Therapy (HAART) on Interleukin 17A (IL-17A) in Normotensive and Preeclamptic Black South African Women

Cited by 4 publications

References 37 publications

Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study

Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study

Evaluating the association of antiretroviral therapy and immune status with hypertensive disorders of pregnancy among people with HIV

Circulating levels of inflammatory mediators in pregnant people living with HIV according to antiretroviral therapy regimen

Contact Info

Product

Resources

About